New products

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.

The therapy is now the first and only oral on demand treatment option for the condition.

From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.